So I've been looking at the biotech sector lately and honestly, there's something interesting brewing here that a lot of people seem to be sleeping on.

The thing is, when the broader market gets shaky and everyone's panicking about recessions, biotech stocks to buy actually start looking more attractive. Why? Because people don't stop needing medical solutions no matter what the economy's doing. The sector itself has serious tailwinds – we're talking about an ecosystem that hit $1.55 trillion in valuation and is projected to keep expanding at double-digit growth rates over the next several years.

I started digging into some of the names that caught my attention, and there are actually a few biotech stocks to buy that are trading at reasonable valuations right now compared to where they were.

CRISP is the obvious one everyone knows about – gene-editing technology with real potential to address genetic disorders. The stock's been volatile, and yeah, profitability is still a question mark. But they showed some promise recently by beating earnings expectations, which tells me the underlying business might actually be moving in the right direction. The valuation's come down significantly from where it was.

VYGR is interesting because it's focused on neurological diseases, particularly Alzheimer's. The stock's cheap on a price-to-sales basis, though the revenue projections are a bit messy. Still, given how much demand there is for Alzheimer's treatments, it's worth keeping tabs on.

SRPT is probably the most established of the bunch – they're already generating real revenue from their genetic medicine approach for rare neuromuscular diseases. The growth trajectory they're projecting actually looks pretty solid, and the valuation doesn't feel stretched relative to those growth expectations.

Then you've got RGNX, BPMC, DTIL, and ALLO – all operating in different niches within precision medicine and gene therapy. DTIL is particularly interesting because they're actually profitable, which is rare in this space. ALLO is the most speculative, but if their CAR-T approach works out, the upside could be substantial.

The broader thesis here is that biotech stocks to buy right now represent a sector that's fundamentally recession-resistant. Society needs solutions for cancer, autoimmune diseases, genetic disorders – that demand isn't going away. And with government support for biotech initiatives, there's structural backing for the space.

Obviously, biotech is high-risk. Most of these companies are pre-profitability or barely profitable. But if you've got a time horizon and can stomach volatility, there are some genuinely compelling biotech stocks to buy at current prices. The valuations have compressed enough that the risk-reward setup feels more favorable than it did a year or two ago.

Worth doing your own research, but I'm keeping a close eye on this sector.